TW200738671A - Compounds for the inhibition of integrins and use thereof - Google Patents
Compounds for the inhibition of integrins and use thereofInfo
- Publication number
- TW200738671A TW200738671A TW096103577A TW96103577A TW200738671A TW 200738671 A TW200738671 A TW 200738671A TW 096103577 A TW096103577 A TW 096103577A TW 96103577 A TW96103577 A TW 96103577A TW 200738671 A TW200738671 A TW 200738671A
- Authority
- TW
- Taiwan
- Prior art keywords
- substituted
- membered rings
- group
- nrc
- radical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
The present invention is related to a compound of formula (I) G-Z-A-Ar-Y-Ψ (I) wherein A is a radical selected from the group comprising nonaromatic heterocyclic and homocyclic ring systems; Ar is a radical which is either absent or present, whereby if Ar is present, Ar is selected from the group comprising 3- to 9-membered rings, or if Ar is present, Ar is a polycyclic ring system selected from the group comprising 4,4-membered rings, 4,5-membered rings, 4,6-membered rings, 5,5-membered rings, 5,6-membered rings, 6,6-membered rings, 6,7-membered rings, 7,7-membered rings, 6,5,6-membered rings, 6,6,6-membered rings, 6,7,6-membered rings; Z and Y are radicals individually and independently selected from the group comprising (CH2)n-E-(CH2)m-L-(CH2)k and (CH2)m-L-(CH2)k, wherein E is a radical which is either absent or present, whereby if E is present, E is selected from the group comprising O, S, NH, NRa, CO, SO, SO2, substituted ethylene and acetylene; L is a radical which is either absent or present, whereby if L is present, L is individually and independently selected from the group comprising O, S, NH, NRb, CO, SO, SO2, substituted ethylene and acetylene; and k, m and n are individually and independently 0, 1, 2 or 3; Ψ is a radical of formula (II), wherein Q is a radical selected from the group comprising a direct bond, C=O, C=S, O, S, CRaRb, NRa-NRb, N=N, CRa=N, N=CRa, (C=O)-O, O-(C=O), SO2, NRa, (C=O)-NRa, NRa-(C=O)-NRb, NRc-(C=O), O-(C=O)-NRc, NRc-(C=O)-O, NRc-(C=S), (C=S)-NRc, NRc-(C=S)-NRd, NRc-SO2 and SO2-NRc. R1, Ra, Rb, Rc and Rd are radicals which are individually and independently selected from the group comprising H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycloyl, substituted heterocycloyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy, alkyloxyalkyl, substituted alkyloxyalkyl, alkyloxycycloalkyl, substituted alkyloxycycloalkyl, alkyloxyheterocyclyl, substituted alkyloxyheterocyclyl, alkyloxyaryl, substituted alkyloxyaryl, alkyloxyheteroaryl, substituted alkyloxyheteroaryl, alkylthioalkyl, substituted alkylthioalkyl, alkylthiocycloalkyl and substituted alkylthiocycloalkyl, hydroxy, substituted hydroxy, oxo, thio, substituted thio, aminocarbonyl, substituted aminocarbonyl, formyl, substituted formyl, thioformyl, substituted thioformyl, amino, substituted amino, hydroxyl, substituted hydroxyl, mercapto, substituted mercapto, hydrazino, substituted hydrazino, diazene, substituted diazene, imine, substituted imine, amidino, substituted amidino, iminomethylamino, substituted iminomethylamino, ureido, substituted ureido, formylamino, substituted formylamino, aminocarbonyloxy, substituted aminocarbonyloxy, hydroxycarbonylamino, substituted hydroxycarbonylamino, hydroxycarbonyl, substituted hydroxycarbonyl, formyloxy, substituted formyloxy, thioformylamino, substituted thioformylamino, ,aminothiocarbonyl, substituted aminothiocarbonyl, thioureido, substituted thioureido, sufonyl, substituted sulfonyl, sulfonamino, substituted sulfonamino, aminosulfonyl, substituted aminosulfonyl, cyano, halogen; R2 is a hydrophobic moiety; R3 is a radical selected from the group comprising OH, C1-C8alkyloxy and aryl C0-C6alkyloxy; R4 is a radical selected from the group comprising hydrogen, halogen and C1-C4alkyl; and G is a radical containing one ore more moieties, whereby such moiety is selected from the group comprising NH, OH and a basic moiety.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06002005 | 2006-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200738671A true TW200738671A (en) | 2007-10-16 |
Family
ID=38123801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW096103577A TW200738671A (en) | 2006-01-31 | 2007-01-31 | Compounds for the inhibition of integrins and use thereof |
Country Status (14)
Country | Link |
---|---|
US (1) | US8927534B2 (en) |
EP (1) | EP1979342A1 (en) |
JP (1) | JP2009525296A (en) |
KR (1) | KR20080095854A (en) |
CN (1) | CN101379056A (en) |
AR (1) | AR059224A1 (en) |
AU (1) | AU2007211620A1 (en) |
BR (1) | BRPI0706800A2 (en) |
CA (1) | CA2635403A1 (en) |
MX (1) | MX2008008866A (en) |
RU (1) | RU2008135358A (en) |
TW (1) | TW200738671A (en) |
WO (1) | WO2007088041A1 (en) |
ZA (1) | ZA200804932B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI763733B (en) * | 2016-11-08 | 2022-05-11 | 美商必治妥美雅史谷比公司 | 3-SUBSTITUTED PROPIONIC ACIDS AS αV INTEGRIN INHIBITORS |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR060901A1 (en) | 2006-05-12 | 2008-07-23 | Jerini Ag | HETEROCICLICAL COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE OF THESE |
WO2008093064A1 (en) * | 2007-01-29 | 2008-08-07 | Astrazeneca Ab | L-ALANINE DERIVATIVES AS α5 BETA 1 ANTAGONISTS |
US20090062267A1 (en) * | 2007-01-29 | 2009-03-05 | Astrazeneca Ab | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS |
WO2009002964A1 (en) * | 2007-06-26 | 2008-12-31 | Lexicon Pharmaceuticals, Inc. | Methods of treating serotonin-mediated diseases and disorders |
KR101572929B1 (en) * | 2007-11-15 | 2015-11-30 | 클라노테크 에이비 | Quinoline derivatives and their use as tyrosine kinase inhibitors |
JP5586485B2 (en) * | 2008-03-14 | 2014-09-10 | ビセン メディカル, インコーポレイテッド | Integrin targeting agents and in vivo and in vitro imaging methods using them |
CN102186883B (en) | 2008-09-18 | 2016-08-03 | 西北大学 | Nmda receptor regulator and its purposes |
WO2010062829A1 (en) * | 2008-11-28 | 2010-06-03 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for treating osteoporosis |
DE102009000854A1 (en) * | 2009-02-13 | 2010-08-19 | Ernst-Moritz-Arndt-Universität Greifswald | Osteopontin-receptor-ligand for binding osteopontin receptors of podocytes of the renal corpuscles, useful for treating chronic renal failure |
EP2547693B1 (en) | 2010-03-19 | 2015-03-11 | H. Lee Moffitt Cancer Center & Research Institute | Integrin interaction inhibitors for the treatment of cancer |
TR201908596T4 (en) | 2013-01-29 | 2019-07-22 | Aptinyx Inc | Spiro-lactam NMDA receptor modulators and their uses. |
SI3929196T1 (en) | 2013-09-24 | 2023-11-30 | Fujifilm Corporation | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof |
US10011635B2 (en) | 2013-09-27 | 2018-07-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Cyclic peptide conjugates and methods of use |
WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
UY35809A (en) * | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (AZA) PIRIDOPIRAZOLOPIRIMIDINONAS AND INDAZOLOPIRIMIDINONAS AND ITS USES |
WO2016145258A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
EP3273965A4 (en) * | 2015-03-26 | 2018-12-05 | Merck Sharp & Dohme Corp. | Composition and methods for treating chronic kidney disease |
WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
EA201892657A1 (en) | 2016-05-19 | 2019-05-31 | Аптиникс Инк. | SPYROLACTAM MODULATORS OF THE NMDA-RECEPTOR AND THEIR APPLICATION |
MX2019001308A (en) | 2016-08-01 | 2019-05-30 | Aptinyx Inc | Spiro-lactam nmda modulators and methods of using same. |
EA201990425A1 (en) | 2016-08-01 | 2019-08-30 | Аптиникс Инк. | SPIRO-LACTAM AND BIS-SPIRO-LACTAM MODULATORS OF THE NMDA RECEPTOR AND THEIR APPLICATION |
US10918637B2 (en) | 2016-08-01 | 2021-02-16 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
JP7036792B2 (en) | 2016-08-01 | 2022-03-15 | アプティニックス インコーポレイテッド | Spiro-lactam NMDA receptor modifiers and their use |
CN109937204B (en) | 2016-08-01 | 2022-11-25 | 阿普廷伊克斯股份有限公司 | Spiro-lactam NMDA receptor modulators and uses thereof |
EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
KR20190112009A (en) * | 2017-01-27 | 2019-10-02 | 장피트 | ROR gamma modulators and uses thereof |
MA47692A (en) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6) |
EP3589627A4 (en) | 2017-02-28 | 2020-08-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
MX2020008107A (en) | 2018-01-31 | 2020-09-25 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof. |
CN112689507A (en) * | 2018-06-27 | 2021-04-20 | 普利安特治疗公司 | Amino acid compounds having unbranched linkers and methods of use thereof |
US20200071322A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibiting (alpha-v)(beta-6) integrin |
CN111991398B (en) * | 2020-09-08 | 2022-03-01 | 中国医科大学附属盛京医院 | Application of benzopyrazines compound in preparation of SOST protein inhibitor |
JP2023545588A (en) * | 2020-10-16 | 2023-10-30 | ツェーエムエム-フォルシュングスツェントルム フュア モレクラレ メディツィン ゲーエムベーハー | Heterocyclic cullin RING ubiquitin ligase compounds and uses thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US203745A (en) * | 1878-05-14 | Improvement in stench-valves for wash-basins | ||
PT1005445E (en) * | 1997-08-22 | 2004-09-30 | Hoffmann La Roche | N-ALCANOYLPHENYL ANALINE DERIVATIVES |
AR013693A1 (en) * | 1997-10-23 | 2001-01-10 | Uriach & Cia Sa J | NEW PIPERIDINES AND PIPERAZINAS AS INHIBITORS OF THE PLAQUETARY AGREGATION |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
ATE542797T1 (en) * | 1998-04-09 | 2012-02-15 | Meiji Seika Pharma Co Ltd | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN ALPHA V BETA 3 ANTAGONISTS |
DE60033684T2 (en) * | 1999-11-18 | 2007-12-06 | Ajinomoto Co., Inc. | phenylalanine derivatives |
US6388084B1 (en) | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
JP3824935B2 (en) * | 1999-12-06 | 2006-09-20 | エフ.ホフマン−ラ ロシュ アーゲー | 4-pyrimidinyl-N-acyl-L-phenylalanine |
AU2001278740B9 (en) * | 2000-08-18 | 2006-09-28 | Ea Pharma Co., Ltd. | Novel phenylalanine derivatives |
TWI290130B (en) * | 2000-09-15 | 2007-11-21 | Pharmacia Corp | 2-Amino-2alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
ATE345127T1 (en) * | 2000-09-29 | 2006-12-15 | Ajinomoto Kk | NEW PHENYLALANINE DERIVATIVES |
ATE468325T1 (en) * | 2001-03-19 | 2010-06-15 | Dainippon Sumitomo Pharma Co | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION CONTAINING SAME |
JP4452899B2 (en) * | 2001-12-13 | 2010-04-21 | 味の素株式会社 | New phenylalanine derivatives |
AU2003235256A1 (en) | 2002-04-19 | 2003-11-03 | Kyowa Hakko Kogyo Co., Ltd. | Phenylalanine derivative |
GB0329584D0 (en) | 2003-12-20 | 2004-01-28 | Tanabe Seiyaku Co | Novel compounds |
CA2555227A1 (en) * | 2004-02-10 | 2005-08-25 | Janssen Pharmaceutica, N.V. | Pyridazinone ureas as antagonists of .alpha.4 integrins |
CA2555594A1 (en) | 2004-02-10 | 2005-08-25 | Janssen Pharmaceutica N.V. | Pyridazinones as antagonists of a4 integrins |
PL1727811T3 (en) * | 2004-03-24 | 2015-04-30 | Shire Orphan Therapies Gmbh | New compounds for the inhibition of angiogenesis and use of thereof |
JP2009516730A (en) | 2005-11-23 | 2009-04-23 | アストラゼネカ アクチボラグ | L-alanine derivative |
US20090137601A1 (en) * | 2005-11-23 | 2009-05-28 | Astrazeneca Ab | L-Phenylalanine Derivatives |
AR060901A1 (en) | 2006-05-12 | 2008-07-23 | Jerini Ag | HETEROCICLICAL COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE OF THESE |
-
2007
- 2007-01-29 AR ARP070100365A patent/AR059224A1/en not_active Application Discontinuation
- 2007-01-31 EP EP07711423A patent/EP1979342A1/en not_active Withdrawn
- 2007-01-31 CA CA002635403A patent/CA2635403A1/en not_active Abandoned
- 2007-01-31 WO PCT/EP2007/000832 patent/WO2007088041A1/en active Application Filing
- 2007-01-31 KR KR1020087017090A patent/KR20080095854A/en not_active Application Discontinuation
- 2007-01-31 AU AU2007211620A patent/AU2007211620A1/en not_active Abandoned
- 2007-01-31 TW TW096103577A patent/TW200738671A/en unknown
- 2007-01-31 MX MX2008008866A patent/MX2008008866A/en unknown
- 2007-01-31 JP JP2008552739A patent/JP2009525296A/en active Pending
- 2007-01-31 US US12/162,798 patent/US8927534B2/en not_active Expired - Fee Related
- 2007-01-31 BR BRPI0706800-0A patent/BRPI0706800A2/en not_active IP Right Cessation
- 2007-01-31 RU RU2008135358/04A patent/RU2008135358A/en not_active Application Discontinuation
- 2007-01-31 CN CNA2007800040609A patent/CN101379056A/en active Pending
-
2008
- 2008-06-04 ZA ZA200804932A patent/ZA200804932B/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI763733B (en) * | 2016-11-08 | 2022-05-11 | 美商必治妥美雅史谷比公司 | 3-SUBSTITUTED PROPIONIC ACIDS AS αV INTEGRIN INHIBITORS |
Also Published As
Publication number | Publication date |
---|---|
MX2008008866A (en) | 2008-10-23 |
ZA200804932B (en) | 2009-06-24 |
AU2007211620A1 (en) | 2007-08-09 |
AR059224A1 (en) | 2008-03-19 |
KR20080095854A (en) | 2008-10-29 |
WO2007088041A1 (en) | 2007-08-09 |
EP1979342A1 (en) | 2008-10-15 |
JP2009525296A (en) | 2009-07-09 |
RU2008135358A (en) | 2010-03-10 |
US20090104116A1 (en) | 2009-04-23 |
CA2635403A1 (en) | 2007-08-09 |
US8927534B2 (en) | 2015-01-06 |
CN101379056A (en) | 2009-03-04 |
BRPI0706800A2 (en) | 2011-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200738671A (en) | Compounds for the inhibition of integrins and use thereof | |
TW200740820A (en) | Fused heterocyclic derivatives and use thereof | |
TW200633991A (en) | Chemical compounds | |
CA1230113A (en) | Method for producing chemical compounds | |
WO2006078283A3 (en) | Quinoxaline inhibitors of hedgehog signalling | |
UA84022C2 (en) | (thio)carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists | |
WO2008007122A3 (en) | Combinations of pyrazole derivatives for the inhibition of cdks and gsk's | |
CO5611110A2 (en) | GLUCOCORTICOID MIMETICS, PROCEDURES FOR THE PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME | |
MY153045A (en) | Oxopyrazine derivative and herbicide | |
EP1661890A4 (en) | Ppar-activating compound and pharmaceutical composition containing same | |
MXPA04008796A (en) | Carbonylamino-derivatives as novel inhibitors of histone deacetylase. | |
MX9710259A (en) | Arthropodicidal and fungicidal cyclic amides. | |
CA2551859A1 (en) | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | |
DE69738225D1 (en) | epoxidation | |
TW200621755A (en) | Oxime ester compound and photopolymerization initiator containing such compound | |
WO2005061458A3 (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
RU2008135995A (en) | Sphingosine-1-Phosphate Binding Inhibitor | |
MY157481A (en) | Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors | |
NZ596653A (en) | Total synthesis of salinosporamide a and analogs thereof | |
NO20064175L (en) | Heterocyclic compound | |
GB0122503D0 (en) | Chemical compounds | |
WO2005080396A3 (en) | Azolopyrimidine compounds and use thereof for combating parasitic fungi | |
EP1637527A4 (en) | Cannabinoid receptor modulator | |
WO2005019191A3 (en) | 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c | |
EP1640369A4 (en) | Thiazolimine compound and oxazolimine compound |